NYXH Nyxoah

Publication relating to transparency notifications

Publication relating to transparency notifications

                

REGULATED INFORMATION

Publication relating to transparency notifications

Mont-Saint-Guibert (Belgium), October 9, 2024, 10:30 pm CET / 4:30 pm ET In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

BlackRock, Inc.

On October 7, 2024, Nyxoah received a transparency notification from BlackRock, Inc. and related persons following a change to BlackRock’s group structure. Based on the notification, BlackRock, Inc. (together with its controlled undertakings) holds 1,116,421 voting rights, consisting of 1,032,521 shares and 83,900 equivalent financial instruments, representing 3.25% of the total number of voting rights on October 1, 2024 (34,389,015).

The notification dated October 3, 2024 contains the following information:

  • Reason for the notification: acquisition or disposal of the control of an undertaking that holds a participating interest in an issuer
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
    • BlackRock, Inc. (with address at 50 Hudson Yards, New York, NY, 10001, U.S.A.)
    • BlackRock Advisors, LLC (with address at 50 Hudson Yards, New York, NY, 10001, U.S.A.)
    • BlackRock Fund Advisors (with address at 400 Howard Street, San Francisco, CA, 94105, U.S.A.)
    • BlackRock Investment Management (UK) Limited (with address at 12 Throgmorton Avenue, London, EC2N 2DL, U.K.)
    • BlackRock Investment Management, LLC (with address at 1 University Square Drive, Princeton, NJ, 8540, U.S.A.)
  • Date on which the threshold was crossed: October 1, 2024
  • Threshold that is crossed: 3%
  • Denominator: 34,389,015
  • Notified details:
A) Voting rightsPrevious notificationAfter the transaction
 # of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
BlackRock, Inc.00 0.00% 
BlackRock Advisors, LLC1,016,861 1,006,161  2.93% 
BlackRock Fund Advisors4646 0.00% 
BlackRock Investment Management (UK) Limited1,0801,080 0.00% 
BlackRock Investment Management, LLC25,23425,234 0.07% 
Subtotal1,043,221 1,032,521 3.00% 
 TOTAL1,032,52103.00%0.00%



B) Equivalent financial instrumentsAfter the transaction
Holders of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
BlackRock Advisors, LLCSecurities Lent  83,0000.24%physical
BlackRock Fund AdvisorsSecurities Lent  9000.00%physical
 TOTAL  83,9000.24% 



 TOTAL (A & B)# of voting rights% of voting rights 
    1,116,4213.25% 
  • Full chain of controlled undertakings through which the holding is effectively held:



BlackRock, Inc.

BlackRock Finance, Inc.

Trident Merger, LLC

BlackRock Investment Management, LLC

BlackRock, Inc.

BlackRock Finance, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock International Holdings, Inc.

BR Jersey International Holdings L.P.

BlackRock Holdco 3, LLC

BlackRock Cayman 1 LP

BlackRock Cayman West Bay Finco Limited

BlackRock Cayman West Bay IV Limited

BlackRock Group Limited

BlackRock Finance Europe Limited

BlackRock Investment Management (UK) Limited

BlackRock, Inc.

BlackRock Finance, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock Holdco 4, LLC

BlackRock Holdco 6, LLC

BlackRock Delaware Holdings Inc.

BlackRock Fund Advisors

BlackRock, Inc.

BlackRock Finance, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock Capital Holdings, Inc.

BlackRock Advisors, LLC

  • Additional information: As a result of the acquisition of Global Infrastructure Partners, there has been a change to BlackRock’s group structure. Upon the close of the transaction, BlackRock, Inc. was renamed BlackRock Finance, Inc. and a NewCo became the publicly listed company with the name BlackRock, Inc.



*

* *

Contact:

Nyxoah

Loic Moreau, CFO



Attachment



EN
09/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
 PRESS RELEASE

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for the second quarter of 2025 and other business updates.  Preliminary, Unaudited Second Quarter 2025 Financial Results and Business U...

 PRESS RELEASE

Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre ...

Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025 Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025  Mont-Saint-Guibert, Belgique – 11 août 2025, 7h00 CET / 01h00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) par la neuromodulation, a annoncé aujourd'hui certains résultats financiers préliminaires non audités pour le deuxième trimestre 2025 et d'autres informations su...

 PRESS RELEASE

Nyxoah Receives Approval from FDA for Genio® System for the Treatment ...

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep ApneaU.S. Commercialization Officially Launched Mont-Saint-Guibert, Belgium – August 8, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Food a...

 PRESS RELEASE

Nyxoah Obtient l'Autorisation de la FDA pour le Système Genio® Destiné...

Nyxoah Obtient l'Autorisation de la FDA pour le Système Genio® Destiné au Traitement de l'Apnée Obstructive du Sommeil INFORMATIONS PRIVILÉGIÉESINFORMATIONS RÉGLEMENTÉES Nyxoah Obtient l'Autorisation de la FDA pour le Système Genio® Destiné au Traitement de l'Apnée Obstructive du SommeilLancement Officiel de la Commercialisation aux États-Unis Mont-Saint-Guibert, Belgique – 8 juillet 2025, 22h10 CET / 16h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch